Ergomed plc, (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, will announce its Preliminary Results for the full year ending 31 December 2018 on 10 April 2019.
Guildford, UK – 2 April 2019:ErgoMed plc, (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, will announce its Preliminary Results for the full year ending 31 December 2018 on 10 April 2019.
Miroslav Reljanović, Executive Chairman and other members of the management team will host a presentation and conference call for analysts at 08:30am BST on the day of the results at the offices of Numis, 10 Paternoster Sq., London EC4M 7LT.
Enquiries:
| Ergomed plc | Tel: +44 (0) 1483 402 975 |
| Miroslav Reljanović (Executive Chairman) | |
| Stuart Jackson (Chief Financial Officer) | |
| Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
| Freddie Barnfield (Nominated Adviser) | |
| James Black (Broker) | |
| Consilium Strategic Communications – for UK enquiries | Tel: +44 (0) 20 3709 5700 |
| Chris Gardner / Mary-Jane Elliott | |
| Matthew Neal / Olivia Manser | |
| MC Services – for Continental European enquiries | Tel: +49 211 5292 5222 |
| Anne Hennecke |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com
